Squarepoint
MPLT icon

Squarepoint’s MapLight Therapeutics MPLT Stock Holding History

Squarepoint’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$160K Buy
+15,735
New +$295K ﹤0.01% 4128

Other funds holding MPLT

Sanofi
Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Market Street Wealth Management Advisors
Market Street Wealth Management Advisors Indianapolis, Indiana $703M AUM 10.22% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return

Squarepoint's MPLT Position: Q3 2026 in Review

Squarepoint opened a new position in MapLight Therapeutics (MPLT) in Q3 2026: 15,735 shares worth $160K. The stake represents ﹤0.01% of the portfolio and ranks #4128 among its holdings.

25 funds tracked by Wall St. Rank hold MPLT as of Q3 2026.

  • Squarepoint held 15,735 shares of MapLight Therapeutics worth $160K as of Q3 2026.
  • MapLight Therapeutics was a new Squarepoint position in Q3 2026.
  • MapLight Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q3 2026, its #4128 holding.
  • 25 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.